IMPACT BIOMEDICAL INC
For the period ended Mar 31, 2024. Filed May 10, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 10, 2024
IBO$4.62+6.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 1. Condensed Consolidated Balance Sheets as of March 31, 2024 (Unaudited) and December 31, 2023
| March 31, 2024 (unaudited) | December 31, 2023 | |
|---|---|---|
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | $2,000 | $1,000 |
| Accounts receivable, net | 128,000 | 128,000 |
| Current portion of notes receivable | 203,000 | 203,000 |
| Prepaid expenses and other current assets | 2,000 | - |
| Total current assets | 335,000 | 332,000 |
| Property, plant and equipment, net | 285,000 | 287,000 |
| Goodwill | 25,093,000 | 25,093,000 |
| Other intangible assets, net | 18,643,000 | 18,921,000 |
| Total assets | $44,356,000 | $44,633,000 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||
| Current liabilities: | ||
| Accounts payable | $1,023,000 | $832,000 |
| Accrued expenses | 47,000 | 230,000 |
| Note payable, related party | 12,787,000 | 12,074,000 |
| Total current liabilities | 13,857,000 | 13,136,000 |
| Deferred tax liability, net | 3,235,000 | 3,235,000 |
| Commitments and contingencies (Note 10) | - | |
| Stockholders’ equity | ||
| Preferred stock, $0.001 par value; 100,000,000 shares authorized, 60,496,041 shares issued and outstanding (60,496,041 on December 31, 2023); Liquidation value $0.001 per share, $60,000 aggregate. $60,000 on December 31, 2023). | 60,000 | 60,000 |
| Common stock, $0.001 par value; 4,000,000,000 shares authorized, 10,000,000 shares issued and outstanding (10,000,000 on December 31, 2023) | 10,000 | 10,000 |
| Additional paid-in capital | 38,113,000 | 38,113,000 |
| Accumulated deficit | (13,923,000) | (12,961,000) |
| Total stockholders’ equity of the Company | 24,260,000 | 25,222,000 |
| Non-controlling interest in subsidiaries | 3,004,000 | 3,040,000 |
| Total stockholders’ equity | 27,264,000 | 28,262,000 |
| Total liabilities and stockholders’ equity | $44,356,000 | $44,633,000 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.